{"gene":"APOA2","run_date":"2026-06-09T22:02:43","timeline":{"discoveries":[{"year":2018,"finding":"The APOA2 promoter -265T>C (rs5082) CC genotype, when combined with high saturated fatty acid (SFA) intake, leads to differential methylation at CpG site cg04436964, which is negatively correlated with APOA2 mRNA expression in blood. CC carriers consuming high-SFA diets show lower APOA2 expression than TT carriers, and this epigenetic-expression difference is associated with altered tryptophan and branched-chain amino acid (BCAA) metabolic pathways.","method":"Epigenome-wide scan, transcription analysis, metabolomics, validated in three independent cohorts (BPRHS, GOLDN, FHS)","journal":"The American journal of clinical nutrition","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (epigenomics, transcriptomics, metabolomics) replicated across three independent cohorts, directly linking genotype to promoter methylation, mRNA expression, and downstream metabolic pathways","pmids":["29901700"],"is_preprint":false},{"year":2024,"finding":"SAMD4B increases APOA2 mRNA instability through 2'-O-methylation modification of its C-terminus. Decreased APOA2 protein in turn attenuates PD-L1 levels via direct protein-protein interaction, implicating the SAMD4B-APOA2-PD-L1 axis in tumor immune evasion in hepatocellular carcinoma.","method":"2'-O-methylation modification assays, multiplex immunofluorescence staining, single-cell RNA sequencing in PDX mouse models, mechanistic interaction studies","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — multiple methods in a single lab (2'-O-methylation, PDX models, scRNA-seq), but direct APOA2–PD-L1 interaction described as 'direct interaction pattern' without full biochemical reconstitution in the abstract","pmids":["38886351"],"is_preprint":false},{"year":2026,"finding":"APOA2 overexpression in HCC upregulates TGF-β secretion (verified by proteomic analysis and measurement in cell culture medium and mouse blood). TGF-β then mediates two downstream effects: (1) reduction of VEGFR-2 expression and induction of endothelial-to-mesenchymal transition in endothelial cells, and (2) initiation of fatty acid oxidation reprogramming and increased free fatty acid uptake in cancer cells, promoting proliferation. TGF-β inhibition abolished these APOA2-mediated effects.","method":"Whole transcriptome sequencing of human HCC specimens, APOA2 overexpression in HCC-bearing mouse model, proteomic analysis, TGF-β inhibition rescue experiments","journal":"Cell death discovery","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (proteomics, transcriptomics, in vivo mouse model, rescue with TGF-β inhibitor) in a single study establishing the mechanistic pathway","pmids":["41760604"],"is_preprint":false},{"year":2025,"finding":"APOA2 expression in HCC negatively correlates with MHC molecule expression and impairs dendritic cell antigen presentation through the PPAR signaling pathway, contributing to an immunosuppressive tumor microenvironment and resistance to combined targeted/immunotherapy.","method":"Spatial transcriptomics, single-cell RNA sequencing, hdWGCNA, KEGG enrichment, CellChat ligand-receptor interaction analysis, validated with TCGA bulk RNA-seq data","journal":"Translational cancer research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — computational/bioinformatic analyses (spatial transcriptomics, scRNA-seq, correlation analyses) without direct functional validation of APOA2-PPAR-DC interaction in vitro or in vivo","pmids":["41158225"],"is_preprint":false},{"year":1988,"finding":"APOA2 was mapped by in situ hybridisation to chromosomal region 1q21-1q23, with DNA hybridisation to somatic cell hybrids confirming localization proximal to 1q23.","method":"In situ hybridisation, somatic cell hybrid analysis","journal":"Human genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct physical mapping by two orthogonal methods (in situ hybridisation and somatic cell hybrids), replicated by subsequent linkage studies","pmids":["3136074"],"is_preprint":false}],"current_model":"APOA2 is a lipoprotein-associated protein encoded at chromosome 1q21-23 whose promoter methylation and expression are regulated by a gene-diet interaction (rs5082 genotype × saturated fat intake) involving CpG methylation at cg04436964 and downstream BCAA/tryptophan metabolic pathway modulation; in hepatocellular carcinoma, APOA2 drives antiangiogenic drug resistance via TGF-β-mediated endothelial-mesenchymal transition and fatty acid oxidation reprogramming, and participates in immune evasion through a SAMD4B-regulated mRNA stability axis that controls PD-L1 levels and through PPAR-pathway-dependent suppression of dendritic cell antigen presentation."},"narrative":{"mechanistic_narrative":"APOA2 is a lipoprotein-associated protein whose expression is shaped by a gene–diet interaction: the promoter -265T>C (rs5082) CC genotype combined with high saturated fat intake drives differential methylation at CpG cg04436964, which inversely correlates with APOA2 mRNA and is linked to altered tryptophan and branched-chain amino acid metabolism [PMID:29901700]. In hepatocellular carcinoma, APOA2 functions as a driver of tumor progression and therapy resistance through several converging mechanisms. APOA2 mRNA stability is controlled post-transcriptionally by SAMD4B via 2'-O-methylation of its C-terminus, and APOA2 protein in turn elevates PD-L1 levels through direct protein–protein interaction, forming a SAMD4B–APOA2–PD-L1 axis that promotes immune evasion [PMID:38886351]. APOA2 overexpression upregulates TGF-β secretion, which reduces VEGFR-2 expression and induces endothelial-to-mesenchymal transition while reprogramming fatty acid oxidation and increasing free fatty acid uptake to promote cancer cell proliferation; TGF-β inhibition abolishes these effects [PMID:41760604]. The gene maps to chromosome 1q21–1q23 [PMID:3136074].","teleology":[{"year":1988,"claim":"Establishing the chromosomal location of APOA2 provided the physical anchor needed to study its genetics and regulation.","evidence":"In situ hybridisation and somatic cell hybrid analysis mapping to 1q21-1q23","pmids":["3136074"],"confidence":"High","gaps":["Mapping alone does not address gene function or regulation","No protein-level characterization"]},{"year":2018,"claim":"It was unknown how diet modulates APOA2 expression; an epigenome-wide approach showed that the rs5082 CC genotype combined with high saturated fat alters cg04436964 methylation, inversely linked to APOA2 mRNA and to BCAA/tryptophan metabolism, establishing a gene-diet-epigenetic regulatory axis.","evidence":"Epigenome-wide scan, transcriptomics, and metabolomics replicated across three independent cohorts (BPRHS, GOLDN, FHS)","pmids":["29901700"],"confidence":"High","gaps":["Mechanism by which methylation alters transcription not resolved","Causal direction between APOA2 and the metabolic pathways not established","Association observed in blood, not tissue-specific"]},{"year":2024,"claim":"To explain APOA2's role in tumor immune evasion, studies identified SAMD4B as a post-transcriptional regulator destabilizing APOA2 mRNA and showed APOA2 protein elevates PD-L1 via direct interaction, defining a SAMD4B-APOA2-PD-L1 axis.","evidence":"2'-O-methylation assays, multiplex immunofluorescence, scRNA-seq in PDX mouse models","pmids":["38886351"],"confidence":"Medium","gaps":["APOA2-PD-L1 interaction described as a pattern without full biochemical reconstitution","No reciprocal validation of the direct interaction","Single-lab study"]},{"year":2025,"claim":"Bioinformatic dissection of the tumor microenvironment linked APOA2 expression to suppressed MHC and impaired dendritic cell antigen presentation through PPAR signaling, contributing to immunotherapy resistance.","evidence":"Spatial transcriptomics, scRNA-seq, hdWGCNA, CellChat, validated with TCGA bulk RNA-seq","pmids":["41158225"],"confidence":"Low","gaps":["Purely computational without in vitro or in vivo functional validation","APOA2-PPAR-DC mechanistic link not directly tested","Correlation does not establish causation"]},{"year":2026,"claim":"The downstream effectors of APOA2-driven progression were defined: APOA2 upregulates TGF-β secretion, which drives endothelial-to-mesenchymal transition with VEGFR-2 loss and fatty acid oxidation reprogramming, explaining antiangiogenic drug resistance.","evidence":"Whole transcriptome sequencing of HCC specimens, APOA2 overexpression mouse model, proteomics, TGF-β inhibition rescue experiments","pmids":["41760604"],"confidence":"Medium","gaps":["Direct mechanism by which APOA2 induces TGF-β secretion unknown","Single study","Relationship to the SAMD4B/PD-L1 and PPAR axes not integrated"]},{"year":null,"claim":"How APOA2's lipoprotein-associated biochemical activity mechanistically connects to its TGF-β, PD-L1, and PPAR-linked roles in hepatocellular carcinoma remains unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structural or biochemical model of APOA2 partner interactions","Integration of metabolic, immune, and angiogenic roles into one mechanism missing","No direct functional validation linking diet-regulated expression to tumor phenotypes"]}],"mechanism_profile":{"molecular_activity":[],"localization":[],"pathway":[],"complexes":[],"partners":["SAMD4B","PD-L1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P02652","full_name":"Apolipoprotein A-II","aliases":["Apolipoprotein A2"],"length_aa":100,"mass_kda":11.2,"function":"May stabilize HDL (high density lipoprotein) structure by its association with lipids, and affect the HDL metabolism","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P02652/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/APOA2","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/APOA2","total_profiled":1310},"omim":[{"mim_id":"621417","title":"APOLIPOPROTEIN A-II DEFICIENCY; APOA2D","url":"https://www.omim.org/entry/621417"},{"mim_id":"608862","title":"NAD(P)HX EPIMERASE; NAXE","url":"https://www.omim.org/entry/608862"},{"mim_id":"606945","title":"LOW DENSITY LIPOPROTEIN RECEPTOR; LDLR","url":"https://www.omim.org/entry/606945"},{"mim_id":"602491","title":"HYPERLIPIDEMIA, FAMILIAL COMBINED, 1; FCHL1","url":"https://www.omim.org/entry/602491"},{"mim_id":"600390","title":"UPSTREAM TRANSCRIPTION FACTOR 2, FOS-INTERACTING; USF2","url":"https://www.omim.org/entry/600390"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"liver","ntpm":33506.8}],"url":"https://www.proteinatlas.org/search/APOA2"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P02652","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P02652","model_url":"https://alphafold.ebi.ac.uk/files/AF-P02652-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P02652-F1-predicted_aligned_error_v6.png","plddt_mean":75.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=APOA2","jax_strain_url":"https://www.jax.org/strain/search?query=APOA2"},"sequence":{"accession":"P02652","fasta_url":"https://rest.uniprot.org/uniprotkb/P02652.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P02652/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P02652"}},"corpus_meta":[{"pmid":"19901143","id":"PMC_19901143","title":"APOA2, dietary fat, and body mass index: replication of a gene-diet interaction in 3 independent populations.","date":"2009","source":"Archives of internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19901143","citation_count":123,"is_preprint":false},{"pmid":"20975728","id":"PMC_20975728","title":"Association between the APOA2 promoter polymorphism and body weight in Mediterranean and Asian populations: replication of a gene-saturated fat interaction.","date":"2010","source":"International journal of obesity (2005)","url":"https://pubmed.ncbi.nlm.nih.gov/20975728","citation_count":80,"is_preprint":false},{"pmid":"26365669","id":"PMC_26365669","title":"Interaction of dietary fat intake with APOA2, APOA5 and LEPR polymorphisms and its relationship with obesity and dyslipidemia in young subjects.","date":"2015","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/26365669","citation_count":54,"is_preprint":false},{"pmid":"11163832","id":"PMC_11163832","title":"Microsatellite DNA assays reveal an allelic imbalance in p16(Ink4), GALT, p53, and APOA2 loci in patients with endometriosis.","date":"2001","source":"Fertility and sterility","url":"https://pubmed.ncbi.nlm.nih.gov/11163832","citation_count":52,"is_preprint":false},{"pmid":"29901700","id":"PMC_29901700","title":"Epigenomics and metabolomics reveal the mechanism of the APOA2-saturated fat intake interaction affecting obesity.","date":"2018","source":"The American journal of clinical nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/29901700","citation_count":50,"is_preprint":false},{"pmid":"16274472","id":"PMC_16274472","title":"Mapping and characterization of the amplicon near APOA2 in 1q23 in human sarcomas by FISH and array CGH.","date":"2005","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16274472","citation_count":26,"is_preprint":false},{"pmid":"12136239","id":"PMC_12136239","title":"Sequence polymorphism at the human apolipoprotein AII gene ( APOA2): unexpected deficit of variation in an African-American sample.","date":"2002","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12136239","citation_count":26,"is_preprint":false},{"pmid":"24382995","id":"PMC_24382995","title":"APOA2 Polymorphism in Relation to Obesity and Lipid Metabolism.","date":"2013","source":"Cholesterol","url":"https://pubmed.ncbi.nlm.nih.gov/24382995","citation_count":23,"is_preprint":false},{"pmid":"3136074","id":"PMC_3136074","title":"Regional chromosomal localisation of APOA2 to 1q21-1q23.","date":"1988","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/3136074","citation_count":21,"is_preprint":false},{"pmid":"25904114","id":"PMC_25904114","title":"APOA2 -256T>C polymorphism interacts with saturated fatty acids intake to affect anthropometric and hormonal variables in type 2 diabetic patients.","date":"2015","source":"Genes & nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/25904114","citation_count":19,"is_preprint":false},{"pmid":"3122561","id":"PMC_3122561","title":"Evidence for linkage of Charcot-Marie-Tooth neuropathy (CMT1) to apolipoprotein A2 (Apo-A2).","date":"1988","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/3122561","citation_count":19,"is_preprint":false},{"pmid":"12119199","id":"PMC_12119199","title":"A candidate gene study in low HDL-cholesterol families provides evidence for the involvement of the APOA2 gene and the APOA1C3A4 gene cluster.","date":"2002","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/12119199","citation_count":16,"is_preprint":false},{"pmid":"14722362","id":"PMC_14722362","title":"Novel QTLs for HDL levels identified in mice by controlling for Apoa2 allelic effects: confirmation of a chromosome 6 locus in a congenic strain.","date":"2004","source":"Physiological genomics","url":"https://pubmed.ncbi.nlm.nih.gov/14722362","citation_count":15,"is_preprint":false},{"pmid":"19216768","id":"PMC_19216768","title":"Evaluating the association of common APOA2 variants with type 2 diabetes.","date":"2009","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19216768","citation_count":14,"is_preprint":false},{"pmid":"25606421","id":"PMC_25606421","title":"Evaluating the association of APOA2 polymorphism with insulin resistance in adolescents.","date":"2014","source":"Meta gene","url":"https://pubmed.ncbi.nlm.nih.gov/25606421","citation_count":12,"is_preprint":false},{"pmid":"2500391","id":"PMC_2500391","title":"The genes for apolipoprotein all (APOA2) and the Duffy blood group (FY) are linked on chromosome 1 in man.","date":"1989","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/2500391","citation_count":11,"is_preprint":false},{"pmid":"33674281","id":"PMC_33674281","title":"apoA2 correlates to gestational age with decreased apolipoproteins A2, C1, C3 and E in gestational diabetes.","date":"2021","source":"BMJ open diabetes research & care","url":"https://pubmed.ncbi.nlm.nih.gov/33674281","citation_count":9,"is_preprint":false},{"pmid":"38886351","id":"PMC_38886351","title":"Synergistic immunochemotherapy targeted SAMD4B-APOA2-PD-L1 axis potentiates antitumor immunity in hepatocellular carcinoma.","date":"2024","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/38886351","citation_count":7,"is_preprint":false},{"pmid":"32120838","id":"PMC_32120838","title":"Association between the APOA2 rs3813627 Single Nucleotide Polymorphism and HDL and APOA1 Levels Through BMI.","date":"2020","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/32120838","citation_count":6,"is_preprint":false},{"pmid":"17485926","id":"PMC_17485926","title":"Quantitative trait locus analysis of plasma cholesterol levels and body weight by controlling the effects of the Apoa2 allele in mice.","date":"2007","source":"The Journal of veterinary medical science","url":"https://pubmed.ncbi.nlm.nih.gov/17485926","citation_count":6,"is_preprint":false},{"pmid":"37511084","id":"PMC_37511084","title":"APOA2: New Target for Molecular Hydrogen Therapy in Sepsis-Related Lung Injury Based on Proteomic and Genomic Analysis.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37511084","citation_count":5,"is_preprint":false},{"pmid":"35883173","id":"PMC_35883173","title":"Dietary acid load modifies the effects of ApoA2-265 T > C polymorphism on lipid profile and serum leptin and ghrelin levels among type 2 diabetic patients.","date":"2022","source":"BMC endocrine disorders","url":"https://pubmed.ncbi.nlm.nih.gov/35883173","citation_count":5,"is_preprint":false},{"pmid":"24004543","id":"PMC_24004543","title":"Novel polymorphisms of the APOA2 gene and its promoter region affect body traits in cattle.","date":"2013","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/24004543","citation_count":4,"is_preprint":false},{"pmid":"38062157","id":"PMC_38062157","title":"CETP and APOA2 polymorphisms are associated with weight loss and healthy eating behavior changes in response to digital lifestyle modifications.","date":"2023","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/38062157","citation_count":3,"is_preprint":false},{"pmid":"34167597","id":"PMC_34167597","title":"ApoA2-256T > C polymorphism interacts with Healthy Eating Index, Dietary Quality Index-International and Dietary Phytochemical Index to affect biochemical markers among type 2 diabetic patients.","date":"2021","source":"The British journal of nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/34167597","citation_count":2,"is_preprint":false},{"pmid":"41158225","id":"PMC_41158225","title":"APOA2 mediates immune therapy tolerance in hepatocellular carcinoma by inhibiting the antigen-presenting function of dendritic cells through the PPAR signaling pathway.","date":"2025","source":"Translational cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/41158225","citation_count":2,"is_preprint":false},{"pmid":"41760604","id":"PMC_41760604","title":"APOA2-mediated endothelial mesenchymal transition and cancer lipid metabolism reprogramming confers antiangiogenic drug resistance through TGF-β.","date":"2026","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/41760604","citation_count":0,"is_preprint":false},{"pmid":"41582167","id":"PMC_41582167","title":"Predictive value of serum apolipoprotein panel (ApoA1 / ApoA2 / ApoA4) as a biomarker for individual radiosensitivity.","date":"2026","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/41582167","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2024.09.28.24314528","title":"Common pathogenic mechanisms for COVID-19 and differentiated thyroid cancer: a proteomic analysis","date":"2024-09-29","source":"bioRxiv","url":"https://doi.org/10.1101/2024.09.28.24314528","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.12.01.24318258","title":"Extreme MetaboHealth scores in three cohort studies associate with plasma protein markers for inflammation and cholesterol transport","date":"2024-12-02","source":"bioRxiv","url":"https://doi.org/10.1101/2024.12.01.24318258","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":18030,"output_tokens":1489,"usd":0.038213,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":8273,"output_tokens":2030,"usd":0.046058,"stage2_stop_reason":"end_turn"},"total_usd":0.084271,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2018,\n      \"finding\": \"The APOA2 promoter -265T>C (rs5082) CC genotype, when combined with high saturated fatty acid (SFA) intake, leads to differential methylation at CpG site cg04436964, which is negatively correlated with APOA2 mRNA expression in blood. CC carriers consuming high-SFA diets show lower APOA2 expression than TT carriers, and this epigenetic-expression difference is associated with altered tryptophan and branched-chain amino acid (BCAA) metabolic pathways.\",\n      \"method\": \"Epigenome-wide scan, transcription analysis, metabolomics, validated in three independent cohorts (BPRHS, GOLDN, FHS)\",\n      \"journal\": \"The American journal of clinical nutrition\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (epigenomics, transcriptomics, metabolomics) replicated across three independent cohorts, directly linking genotype to promoter methylation, mRNA expression, and downstream metabolic pathways\",\n      \"pmids\": [\"29901700\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"SAMD4B increases APOA2 mRNA instability through 2'-O-methylation modification of its C-terminus. Decreased APOA2 protein in turn attenuates PD-L1 levels via direct protein-protein interaction, implicating the SAMD4B-APOA2-PD-L1 axis in tumor immune evasion in hepatocellular carcinoma.\",\n      \"method\": \"2'-O-methylation modification assays, multiplex immunofluorescence staining, single-cell RNA sequencing in PDX mouse models, mechanistic interaction studies\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — multiple methods in a single lab (2'-O-methylation, PDX models, scRNA-seq), but direct APOA2–PD-L1 interaction described as 'direct interaction pattern' without full biochemical reconstitution in the abstract\",\n      \"pmids\": [\"38886351\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"APOA2 overexpression in HCC upregulates TGF-β secretion (verified by proteomic analysis and measurement in cell culture medium and mouse blood). TGF-β then mediates two downstream effects: (1) reduction of VEGFR-2 expression and induction of endothelial-to-mesenchymal transition in endothelial cells, and (2) initiation of fatty acid oxidation reprogramming and increased free fatty acid uptake in cancer cells, promoting proliferation. TGF-β inhibition abolished these APOA2-mediated effects.\",\n      \"method\": \"Whole transcriptome sequencing of human HCC specimens, APOA2 overexpression in HCC-bearing mouse model, proteomic analysis, TGF-β inhibition rescue experiments\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (proteomics, transcriptomics, in vivo mouse model, rescue with TGF-β inhibitor) in a single study establishing the mechanistic pathway\",\n      \"pmids\": [\"41760604\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"APOA2 expression in HCC negatively correlates with MHC molecule expression and impairs dendritic cell antigen presentation through the PPAR signaling pathway, contributing to an immunosuppressive tumor microenvironment and resistance to combined targeted/immunotherapy.\",\n      \"method\": \"Spatial transcriptomics, single-cell RNA sequencing, hdWGCNA, KEGG enrichment, CellChat ligand-receptor interaction analysis, validated with TCGA bulk RNA-seq data\",\n      \"journal\": \"Translational cancer research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — computational/bioinformatic analyses (spatial transcriptomics, scRNA-seq, correlation analyses) without direct functional validation of APOA2-PPAR-DC interaction in vitro or in vivo\",\n      \"pmids\": [\"41158225\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"APOA2 was mapped by in situ hybridisation to chromosomal region 1q21-1q23, with DNA hybridisation to somatic cell hybrids confirming localization proximal to 1q23.\",\n      \"method\": \"In situ hybridisation, somatic cell hybrid analysis\",\n      \"journal\": \"Human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct physical mapping by two orthogonal methods (in situ hybridisation and somatic cell hybrids), replicated by subsequent linkage studies\",\n      \"pmids\": [\"3136074\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"APOA2 is a lipoprotein-associated protein encoded at chromosome 1q21-23 whose promoter methylation and expression are regulated by a gene-diet interaction (rs5082 genotype × saturated fat intake) involving CpG methylation at cg04436964 and downstream BCAA/tryptophan metabolic pathway modulation; in hepatocellular carcinoma, APOA2 drives antiangiogenic drug resistance via TGF-β-mediated endothelial-mesenchymal transition and fatty acid oxidation reprogramming, and participates in immune evasion through a SAMD4B-regulated mRNA stability axis that controls PD-L1 levels and through PPAR-pathway-dependent suppression of dendritic cell antigen presentation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"APOA2 is a lipoprotein-associated protein whose expression is shaped by a gene–diet interaction: the promoter -265T>C (rs5082) CC genotype combined with high saturated fat intake drives differential methylation at CpG cg04436964, which inversely correlates with APOA2 mRNA and is linked to altered tryptophan and branched-chain amino acid metabolism [#0]. In hepatocellular carcinoma, APOA2 functions as a driver of tumor progression and therapy resistance through several converging mechanisms. APOA2 mRNA stability is controlled post-transcriptionally by SAMD4B via 2'-O-methylation of its C-terminus, and APOA2 protein in turn elevates PD-L1 levels through direct protein–protein interaction, forming a SAMD4B–APOA2–PD-L1 axis that promotes immune evasion [#1]. APOA2 overexpression upregulates TGF-β secretion, which reduces VEGFR-2 expression and induces endothelial-to-mesenchymal transition while reprogramming fatty acid oxidation and increasing free fatty acid uptake to promote cancer cell proliferation; TGF-β inhibition abolishes these effects [#2]. The gene maps to chromosome 1q21–1q23 [#4].\",\n  \"teleology\": [\n    {\n      \"year\": 1988,\n      \"claim\": \"Establishing the chromosomal location of APOA2 provided the physical anchor needed to study its genetics and regulation.\",\n      \"evidence\": \"In situ hybridisation and somatic cell hybrid analysis mapping to 1q21-1q23\",\n      \"pmids\": [\"3136074\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mapping alone does not address gene function or regulation\", \"No protein-level characterization\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"It was unknown how diet modulates APOA2 expression; an epigenome-wide approach showed that the rs5082 CC genotype combined with high saturated fat alters cg04436964 methylation, inversely linked to APOA2 mRNA and to BCAA/tryptophan metabolism, establishing a gene-diet-epigenetic regulatory axis.\",\n      \"evidence\": \"Epigenome-wide scan, transcriptomics, and metabolomics replicated across three independent cohorts (BPRHS, GOLDN, FHS)\",\n      \"pmids\": [\"29901700\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which methylation alters transcription not resolved\", \"Causal direction between APOA2 and the metabolic pathways not established\", \"Association observed in blood, not tissue-specific\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"To explain APOA2's role in tumor immune evasion, studies identified SAMD4B as a post-transcriptional regulator destabilizing APOA2 mRNA and showed APOA2 protein elevates PD-L1 via direct interaction, defining a SAMD4B-APOA2-PD-L1 axis.\",\n      \"evidence\": \"2'-O-methylation assays, multiplex immunofluorescence, scRNA-seq in PDX mouse models\",\n      \"pmids\": [\"38886351\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"APOA2-PD-L1 interaction described as a pattern without full biochemical reconstitution\", \"No reciprocal validation of the direct interaction\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Bioinformatic dissection of the tumor microenvironment linked APOA2 expression to suppressed MHC and impaired dendritic cell antigen presentation through PPAR signaling, contributing to immunotherapy resistance.\",\n      \"evidence\": \"Spatial transcriptomics, scRNA-seq, hdWGCNA, CellChat, validated with TCGA bulk RNA-seq\",\n      \"pmids\": [\"41158225\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Purely computational without in vitro or in vivo functional validation\", \"APOA2-PPAR-DC mechanistic link not directly tested\", \"Correlation does not establish causation\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"The downstream effectors of APOA2-driven progression were defined: APOA2 upregulates TGF-β secretion, which drives endothelial-to-mesenchymal transition with VEGFR-2 loss and fatty acid oxidation reprogramming, explaining antiangiogenic drug resistance.\",\n      \"evidence\": \"Whole transcriptome sequencing of HCC specimens, APOA2 overexpression mouse model, proteomics, TGF-β inhibition rescue experiments\",\n      \"pmids\": [\"41760604\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct mechanism by which APOA2 induces TGF-β secretion unknown\", \"Single study\", \"Relationship to the SAMD4B/PD-L1 and PPAR axes not integrated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How APOA2's lipoprotein-associated biochemical activity mechanistically connects to its TGF-β, PD-L1, and PPAR-linked roles in hepatocellular carcinoma remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural or biochemical model of APOA2 partner interactions\", \"Integration of metabolic, immune, and angiogenic roles into one mechanism missing\", \"No direct functional validation linking diet-regulated expression to tumor phenotypes\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [],\n    \"localization\": [],\n    \"pathway\": [],\n    \"complexes\": [],\n    \"partners\": [\"SAMD4B\", \"PD-L1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":3,"faith_total":4,"faith_pct":75.0}}